Table I.
Patients’ characteristics
| Characteristics | Dabigatran (n=31) | Apixaban (n=38) | Edoxaban (n=29) | Rivaroxaban (n=39) |
|---|---|---|---|---|
| Age (years) | 69 [49.8 – 78] | 75,5 [71 – 82] | 78 [70 – 84] | 74 [68 – 79] |
| Weight (kg) | 75 [60–99] | 81 [69–85] | 73 [63–82] | 74 [62–83] |
| Body mass index | 25.7 [23.2–32.3] | 27.1 [24.5–30.5] | 25.9 [23.4–28.4] | 25.8 [23.5–27.8] |
| Male/females (n/n) | 19/12 | 24/14 | 11/18 | 18/21 |
| NVAF/VTE (n/n) | 15/16 | 19/19 | 19/10 | 19/20 |
| Daily dose of DOAC (n) | 2×150 mg (25) 2×110 mg (6) |
2×5 mg (29) 2×2,5 mg (9) |
60 mg (23) 30 mg (6) |
20 mg (31) 15 mg (8) |
| Smokers (%) | 3.2 | 0 | 0 | 0 |
| Diabetes (%) | 3.2 | 18.4 | 13.8 | 5.1 |
| Hypertension (%) | 54.8 | 57.9 | 48.3 | 56.4 |
| Antiplatelet therapy (%) | 6.5 | 13.2 | 13.8 | 23.1 |
| Drug concentration at C-Trough (ng/mL) * | 63 [45 – 119] | 94 [56 – 130] | 29 [21 – 44] | 34 [28 – 44] |
| Drug concentration at C-Peak (ng/mL) * | 152 [91 – 230] | 172 [130 – 288] | 266 [180 – 347] | 205 [131 – 274] |
Data are presented as median [interquartile range], number or %.
*
, There were no differences in drug levels between patients taking high or low doses of direct oral anticoagulants.
NVAF: non-valvular atrial fibrillation; VTE: venous thromboembolism; DOAC: direct oral anticoagulant.